이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a)

A Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial of YKYY032 Injection in Adults With Hyperlipoproteinemia (a)

Phase II clinical trial to evaluate the efficacy and safety of YKYY032 injection in adults with hyperlipoproteinemia (a)

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

This is a randomized, double-blind, parallel, placebo-controlled Phase II clinical study, aiming to evaluate the efficacy and safety of YKYY032 injection in adult patients with hyperlipoproteinemia (a).

연구 유형

중재적

등록 (추정된)

192

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100034
        • Peking University First Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Before starting any research on a specific activity/program, a written informed consent must be provided;

  2. For both males and females, the age at signing the Informed Consent Form (ICF) should be between 18 and 80 years;

  3. The body mass index should be within the range of 18.5 - 40 kg/㎡ (including the boundary values);

  4. During the pre-screening period (if any) and the screening period, the fasting Lp(a) measured in the central laboratory of the trial participants should be ≥ 150 nmol/L;

  5. According to one of the following criteria, the participants are clinically diagnosed with ASCVD, including but not limited to:

    1. Having a history of coronary artery revascularization through percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG);
    2. Diagnosed with coronary artery disease, with or without a previous myocardial infarction;
    3. Diagnosed with atherosclerotic cerebrovascular disease;
    4. Diagnosed with peripheral artery disease; or without a clinical history of ASCVD, but meeting the definition of high-risk individuals for ASCVD in the overall risk assessment flowchart for ASCVD in Chinese lipid management guidelines (2023) (see Appendix 16.1 for the overall risk assessment flowchart for ASCVD in Chinese adults);
  6. For the trial participants who receive the following drug treatments, their treatment plans must be stable for at least 4 weeks before signing the screening ICF, and are expected to remain stable until the end of the follow-up period after the last administration of the trial drug:

    1. Lipid-lowering drugs (statins, ezetimibe, PCSK9 inhibitors, niacin, fibrates, fish oil or other products containing ω-3 fatty acids, including over-the-counter drugs [OTC]);
    2. Testosterone, estrogen, anti-estrogen, progesterone, progestin, selective estrogen receptor modulators and growth hormone.
  7. Female trial participants are not pregnant or breastfeeding; fertile female and male trial participants must have an acceptable contraceptive method from the time of signing the ICF until 12 months after the last administration of the trial drug (see Appendix 16.2 for the requirements for trial participants' contraception); males are not allowed to donate sperm, and females are not allowed to donate eggs;

  8. They are willing to follow the research procedures stipulated in this protocol (including follow-up) and are willing to cooperate fully with the researchers.

Exclusion Criteria:

  1. Clinical evidence of active liver disease or liver dysfunction in the past or currently exists, defined as AST or ALT ≥ 2 times the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5 times the ULN at the screening period (except for participants diagnosed with Gilbert syndrome);
  2. Estimated glomerular filtration rate (eGFR) calculated using the Chronic Kidney Disease - Epidemiology Collaboration (CKD-EPI) creatinine clearance formula is < 60 mL/min/1.73 ㎡ during the screening period;
  3. Any recent major cardiovascular event (ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, unstable angina pectoris, coronary or peripheral artery revascularization, major cardiac surgery, stroke or transient ischemic attack, acute limb ischemia) or non-cardiac major surgery within 6 months before randomization;
  4. Any planned cardiac surgery, PCI or carotid artery stenting procedure during the study period, or planned non-cardiac major surgery;
  5. Moderate to severe heart failure (NYHA functional class III or IV at the screening period) or previously known left ventricular ejection fraction < 50%;
  6. Uncontrolled hypertension (systolic blood pressure [SBP] ≥ 160 mmHg or diastolic blood pressure [DBP] ≥ 100 mmHg);
  7. Presence of uncontrolled arrhythmia within 3 months before randomization, defined as recurrent and symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or drug-uncontrolled supraventricular tachycardia;
  8. Any malignancy within 5 years before randomization (successfully treated non-melanoma skin cancer, cervical carcinoma in situ, breast duct carcinoma, or stage 1 prostate cancer excluded);
  9. Any hereditary or other bleeding disorders;
  10. Fasting triglycerides ≥ 500 mg/dL (5.65 mmol/L) at the screening period;
  11. Fasting LDL-C ≥ 4.9 mmol/L (190 mg/dL) at the screening period;
  12. Presence of type 1 diabetes or poorly controlled type 2 diabetes (defined as requiring hospitalization for ketoacidosis or hyperosmolar hyperglycemic state, or glycated hemoglobin [HbA1c] ≥ 8.5% at the screening period, or hospitalization due to poor glycemic control) within 3 months before randomization;
  13. Uncontrolled hyperthyroidism or hypothyroidism (stable treatment with abnormal thyroid hormone or unrelieved clinical symptoms);
  14. Any active infection or major hematological, renal, metabolic, gastrointestinal or endocrine dysfunction requiring systemic antiviral or antimicrobial treatment by the investigator's judgment before randomization;
  15. Evidence of acute or chronic hepatitis B or hepatitis C at the screening period (positive for hepatitis B surface antigen [HBsAg]; or positive for hepatitis C antibody [HCV-Ab]), or human immunodeficiency virus (HIV) infection (positive for HIV antibody), or active syphilis infection (positive for Treponema pallidum antibody);
  16. Any ASO, small interfering RNA (siRNA) treatment (such as Inclisiran sodium injection) or any experimental treatment targeting Lp(a) within 12 months before randomization;
  17. Stable use of immunosuppressants, or stable use of corticosteroids (excluding topical/inhaled use) within 3 months before randomization (continuous use >14 days is considered stable use); or regular systemic corticosteroid use within 4 weeks before the first dose; or expected need for prednisone >20 mg/day or equivalent;
  18. Currently receiving, or having received lipoprotein apheresis within 3 months before randomization, or planning to receive lipoprotein apheresis during the study;
  19. Have homozygous familial hypercholesterolemia (HoFH) or have received lomitapide within 12 months prior to randomization;
  20. Are known to be allergic to any component of YKYY032 injection, or have a history or current severe allergic reaction;
  21. Have participated in or plan to participate in a drug clinical trial within 3 months prior to screening, or within the trial period (excluding non-interventional studies and those who only signed the ICF but did not receive study intervention);
  22. Have had or currently have drug abuse or alcoholism (for men, an average weekly alcohol intake of more than 14 units, for women, more than 7 units [1 unit = 360 mL beer; or 150 mL wine; or 45 mL distilled spirits]);
  23. Have received any known herbal medicine (including but not limited to: hawthorn, salvia miltiorrhiza), vitamin (including but not limited to: niacin), or supplement (including but not limited to: red yeast rice, omega-3 fatty acids) within 30 days prior to randomization, except for those who have been using lipid-lowering drugs stably for 4 weeks prior to screening (see item 6 of the inclusion criteria);
  24. Have had or currently have any underlying disease or mental condition that the investigator considers may affect the safety of the study participants during the study, or interfere with the participation or completion of the study, or affect the interpretation of data.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: YKYY032 group

Drug: YKYY032 Injection Subcutaneous administration of YKYY032 on Day 1 and Day 180 (2 doses, approximately 6 months apart)

Drug: YKYY032 Injection Subcutaneous administration of YKYY032 on Day 1 and Day 180 (2 doses, approximately 6 months apart)

위약 비교기: YKYY032 Placebo group

Drug: YKYY032 Placebo Subcutaneous administration of matching placebo on Day 1 and Day 180 (2 doses, approximately 6 months apart)

Drug: YKYY032 Placebo Subcutaneous administration of matching placebo on Day 1 and Day 180 (2 doses, approximately 6 months apart)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
The percentage change from baseline in time average Lp(a) over Days 60-180.
기간: Baseline, Days 60 - 180
Baseline, Days 60 - 180

2차 결과 측정

결과 측정
기간
The proportion of participants achieving Lp(a) < 125 nmol/L and < 75 nmol/L at Days 60, 180, 240, 360 and 540.
기간: Days 60, 180, 240, 360 and 540
Days 60, 180, 240, 360 and 540
The percentage change of Lp(a) from the baseline at Days 60, 180, 240, 360 and 540.
기간: Baseline, Days 60, 180, 240, 360 and 540
Baseline, Days 60, 180, 240, 360 and 540
The absolute value of the change of Lp(a) from the baseline at Days 60, 180, 240, 360 and 540.
기간: Baseline, Days 60, 180, 240, 360 and 540
Baseline, Days 60, 180, 240, 360 and 540
The percentage change of LDL-C from the baseline at Days 60, 180, 240, 360 and 540.
기간: Baseline, Days 60, 180, 240, 360 and 540
Baseline, Days 60, 180, 240, 360 and 540
The percentage change of ApoB from the baseline at Days 60, 180, 240, 360 and 540.
기간: Baseline, Days 60, 180, 240, 360 and 540
Baseline, Days 60, 180, 240, 360 and 540
The percentage change from baseline in other lipid parameters, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and non-high-density lipoprotein cholesterol (non-HDL-C) at Days 60, 180, 240, 360 and 540.
기간: Baseline, Days 60, 180, 240, 360 and 540
Baseline, Days 60, 180, 240, 360 and 540
Percent change in High-sensitivity C-reactive Protein (hsCRP) from baseline.
기간: Baseline, Days 60, 180, 240, 360 and 540
Baseline, Days 60, 180, 240, 360 and 540
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of YKYY032
기간: Day 1: pre-dose, post-dose 1-3 hours, 3-6 hours, 7-9 hours, 22-26 hours (Day 2), 46-50 hours (Day 3); Day 180: 1-3 hours, 3-6 hours, 7-9 hours, 22-26 hours (Day 181), 46-50 hours (Day 182) post-dose
Day 1: pre-dose, post-dose 1-3 hours, 3-6 hours, 7-9 hours, 22-26 hours (Day 2), 46-50 hours (Day 3); Day 180: 1-3 hours, 3-6 hours, 7-9 hours, 22-26 hours (Day 181), 46-50 hours (Day 182) post-dose
The incidence and severity of adverse events (TEAE); Vital signs, physical examination results, laboratory test results, 12-lead electrocardiogram (ECG), etc.
기간: During the clinical trial period, up to Day 540.
During the clinical trial period, up to Day 540.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 20일

기본 완료 (추정된)

2028년 12월 30일

연구 완료 (추정된)

2029년 5월 31일

연구 등록 날짜

최초 제출

2026년 10월 19일

QC 기준을 충족하는 최초 제출

2026년 10월 27일

처음 게시됨 (실제)

2026년 11월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 27일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CLSP-YKYY032-Z02

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .